Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3928/01484834-20220705-02 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Socio-spatial vulnerability index of type 2 diabetes mellitus inMexico in 2020.
Geospat Health
January 2025
Environmental Agenda, Universidad Autónoma de San Luis Potosí, San Luis Potosí.
This study aimed to estimate a socio-spatial vulnerability index for type 2 diabetes mellitus (T2DM) at the municipal level in Mexico for 2020. It incorporated factors such as poverty, social backwardness, marginalization index, and human development index. This retrospective ecological study analyzed 317,011 incident cases of T2DM in 2020.
View Article and Find Full Text PDFNighttime Cough Characteristics in Chronic Obstructive Pulmonary Disease Patients.
Sensors (Basel)
January 2025
Department of Academic Respiratory Medicine, Centre for Cardiovascular and Metabolic Research, Hull York Medical School, Cottingham HU16 5JQ, UK.
Coughing is a symptom of many respiratory diseases. An increased amount of coughs may signal an (upcoming) health issue, while a decreasing amount of coughs may indicate an improved health status. The presence of a cough can be identified by a cough classifier.
View Article and Find Full Text PDFWhy does research matter to psychiatrists?
Brain Neurosci Adv
January 2025
Academic Faculty, Royal College of Psychiatrists, London, UK.
Sphingosine 1-phosphate acts as proliferative and fibrotic cue in leiomyoma cells.
F S Sci
December 2024
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Objective: To determine whether the bioactive sphingolipid sphingosine 1-phosphate (S1P) modulates cellular proliferation and synthesis of fibrotic proteins in leiomyoma differently than myometrial cells.
Design: A basic science study using human leiomyoma and myometrial cells.
Patient(s): Not applicable.
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.
Diabetes Ther
January 2025
Division of Endocrinology and Metabolism, University of British Columbia, Vancouver, Canada.
Article Synopsis
- Oral semaglutide is a diabetes medication that improves blood sugar levels and has been evaluated in multiple countries through the PIONEER REAL program, focusing on its clinical and patient-reported outcomes.
- * In a pooled analysis of 1615 participants, significant reductions in glycated hemoglobin (HbA) by 1.0% and body weight by 5.0% were observed after 38 weeks of treatment, along with increased treatment satisfaction.
- * The analysis revealed that shorter duration of type 2 diabetes was associated with greater improvements in HbA and body weight, while no significant age-related effects were found on clinical outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!